Article
Streamlined Biosimilar Approvals: What The End Of Biosimilar Phase III Trials Means For Innovative Pharmaceutical Patent Holders
The U.S. Food and Drug Administration (FDA) has released a landmark draft guidance on biosimilar submission requirements (the "draft guidance", link here).
McCarthy Tétrault LLP